Blood Coagulation Factor Ii Or Factor Ii + Vii + Ix + X, I.e., Prothrombin Complex Or Factor Patents (Class 530/384)
-
Patent number: 7015194Abstract: The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.Type: GrantFiled: October 16, 2002Date of Patent: March 21, 2006Assignee: Novo Nordisk A/SInventor: Marianne Kjalke
-
Patent number: 7015193Abstract: Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.Type: GrantFiled: April 19, 2002Date of Patent: March 21, 2006Assignee: University of VermontInventors: Saulius Butenas, Kenneth G. Mann, Kathleen Brummel
-
Patent number: 7005271Abstract: The present invention relates to determining the prethrombotic state, in particular determining an amount or presence of circulating microparticles and/or stimulated procoagulant cells.Type: GrantFiled: June 7, 2000Date of Patent: February 28, 2006Inventors: Jean-Marie Freyssinet, Benedicte Antoni, Frederic Donie, Helmut Lill
-
Patent number: 7001989Abstract: The present invention pertains to a pharmaceutical conjugate comprising an insoluble carrier to which first and second active agents are bound, respectively via a first linker to a first functional group on the carrier and via a second linker to a second functional group on the carrier. For example, fibrinogen and Factor VIII can be independently linked to albumin microcapsules.Type: GrantFiled: November 22, 2002Date of Patent: February 21, 2006Assignee: Elan Drug Delivery Ltd.Inventors: Nicola Jane Church, Roy Harris
-
Patent number: 6992061Abstract: The invention relates to a method of removing endotoxin from preparation of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this depyrogenation step, and to the depyrogenated product and its clinical uses.Type: GrantFiled: February 26, 2002Date of Patent: January 31, 2006Assignee: National Blood AuthorityInventors: John Edward More, Jacqueline Rott, David Roger Lewin
-
Patent number: 6967239Abstract: Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filtering the solution through a hydrophilic virus filter.Type: GrantFiled: December 14, 1998Date of Patent: November 22, 2005Assignee: Laboratoire Francias du Franctionnement et des BiotechnologiesInventors: Abdessatar Chtourou, Michel Nogre, Pierre Porte
-
Patent number: 6960657Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.Type: GrantFiled: October 28, 2002Date of Patent: November 1, 2005Assignee: Novo Nordisk Healthcare A/GInventors: Egon Persson, Ole Hvilsted Olsen
-
Patent number: 6958322Abstract: This invention describes a factor Xa analog which has a substitution of a minimum of one of the amino acid between Glu226 and Arg234 and possibly Ile235, relative to the amino acid numbering according to FIG. 1, a preparation containing the activated form of the factor X analog, and a method for the production of these molecules.Type: GrantFiled: August 4, 2000Date of Patent: October 25, 2005Assignee: Baxter AktiengesellschaftInventors: Michele Himmelspach, Uwe Schlokat
-
Patent number: 6913900Abstract: A activator for prekallikrein includes isolated, purified, or substantially purified heat shock protein 90, a phosphate ion, and mixtures thereof. The prekallikrein activator is part of an in vitro system for activating prekallikrein in the absence of FXIIa. The system includes the activator, high-molecular weight kininogen, and zinc ions. A method for activating prekallikrein to produce kallikrein in the absence of FXIIa includes mixing prekallikrein with the activator and a composition comprising high molecular weight kininogen and zinc ions. A method for evaluating the activity of a test drug for the production of kallikrein comprises activating prekallikrein and determining the kallikrein produced. The activity (promoting or inhibiting ability) of the tested drug against the production of kallikrein in the absence of FXIIa can be easily measured. The test drug may be an analgesic, anti-allergy, anti-inflammatory drug.Type: GrantFiled: August 23, 2002Date of Patent: July 5, 2005Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Allen P. Kaplan, Kusumam Joseph
-
Patent number: 6903069Abstract: The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.Type: GrantFiled: October 2, 2001Date of Patent: June 7, 2005Assignee: Novo Nordisk Health Care A/SInventors: Hans Kurt Pingel, Niels Kristian Klausen
-
Patent number: 6893831Abstract: The present invention provides an immunoassay for specifically measuring with high sensitivity PIVKA-II in serum or plasma through antigen-antibody reaction by adding an animal serum containing thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents. The immunoassay of the invention comprises the steps of adding thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents, and measuring PIVKA-II in serum or plasma.Type: GrantFiled: June 1, 2000Date of Patent: May 17, 2005Assignee: Sanko Junyaku Co., Ltd.Inventors: Motohito Kanashima, Tomohide Asai, Hiroki Takahashi, Yoshiyuki Asai
-
Patent number: 6872808Abstract: Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.Type: GrantFiled: February 4, 2000Date of Patent: March 29, 2005Assignee: Corvas International, Inc.Inventors: George Phillip Vlasuk, Patrick Eric Hugo Stanssens, Joris Hilda Lieven Messens, Marc Josef Lauwereys, Yves Rene LaRoche, Laurent Stephane Jespers, Yannick Georges Jozef Gansemans, Matthew Moyle, Peter W. Bergum
-
Patent number: 6869790Abstract: The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is possible with this cDNA not only to obtain factor XIIIa by gene manipulation in high purity but also to prepare diagnostic aids which permit the analysis of genetic factor XIIIa defects. Furthermore, it is possible on the basis of the amino acid sequence to prepare antibodies which are suitable for diagnostic aids and antibody columns.Type: GrantFiled: March 12, 1993Date of Patent: March 22, 2005Assignee: Aventis Behring GmbHInventors: Ulrich Grundmann, Egon Amann, Gerd Zettlmeissl
-
Patent number: 6869934Abstract: The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.Type: GrantFiled: July 18, 2001Date of Patent: March 22, 2005Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Hiroshi Mizokami, Shinichi Furukawa, Keishin Sugawara, Tatsufumi Onchi, Kazuhiro Komatsu, Satoshi Koyanagi, Hideo Yoshizaki
-
Patent number: 6858587Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.Type: GrantFiled: November 1, 2002Date of Patent: February 22, 2005Assignee: Novo Nordisk Pharmaceuticals, Inc.Inventors: Brit Binow Sorensen, Lars Christian Petersen
-
Patent number: 6833352Abstract: The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration. Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream in biologically active form and in adequate concentrations, and favorable pharmacokinetic properties.Type: GrantFiled: October 25, 2001Date of Patent: December 21, 2004Assignee: Novo Nordisk Pharmaceuticals, Inc.Inventors: Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen
-
Patent number: 6825323Abstract: The combination of recombinant factor VIIa and fibrinogen is effective in treatment for bleeding where direct pressure, tourniquets, indirect pressure, surgical ligation, bandaging, and transfusion of blood or plasma products are typically used. The combination of factor VIIa and fibrinogen is administered intravenously, either sequentially or simultaneously. The compositions may be safely circulated in the blood vessels to sites of injury. This is effective for single or multiple external or internal wounds.Type: GrantFiled: January 10, 2001Date of Patent: November 30, 2004Assignee: The United States of America as represented by the Secretary of the ArmyInventor: John R. Hess
-
Patent number: 6818439Abstract: Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 105 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of the human.Type: GrantFiled: December 30, 1997Date of Patent: November 16, 2004Assignee: Chiron CorporationInventors: Douglas J. Jolly, Stephen Chang, James G. Respess, Nicholas J. DePolo, David Chi-Tang Hsu, Carlos E. Ibanez, Judith Greengard, Lee Will
-
Patent number: 6815533Abstract: The present invention is directed at a method of processing an aqueous solution of protein C into a state suitable for storage, handling, and recovery. The present invention provides aqueous activated protein C solutions and an improved method of processing such solutions into cryogranules.Type: GrantFiled: January 22, 2001Date of Patent: November 9, 2004Assignee: Eli Lilly and CompanyInventors: Jeffrey Clayton Baker, Nancy Delores Jones
-
Publication number: 20040197875Abstract: Modified human factor VIII cDNA wherein mutations are inserted either in the wild-type factor VIII cDNA or in a factor VIII cDNA in which the B-domain is partially or completely deleted and may be replaced by a DNA linker segment andType: ApplicationFiled: November 26, 2003Publication date: October 7, 2004Inventors: Hans-Peter Hauser, Thomas Weimer, Martin Phillips
-
Publication number: 20040185535Abstract: The invention provides a method for industrial-scale production of FVII polypeptides in mammalian cell culture free of animal-derived components.Type: ApplicationFiled: March 21, 2003Publication date: September 23, 2004Inventors: Giles Wilson, Ida Molgaard Knudsen
-
Publication number: 20040185534Abstract: The invention relates to methods for cultivating mammalian cells and for producing recombinant proteins in large-scale cultures of such cells. The proteins are, e.g., Factor VII or Factor VII-related polypeptides.Type: ApplicationFiled: March 21, 2003Publication date: September 23, 2004Inventor: Ida Molgaard Knudsen
-
Patent number: 6794493Abstract: Mutant antithrombin modified to carry a more positive charge in the H-helix is provided. The modified antithrombin modulates the activities of thrombin, and extends the bioavailability of factor VIII.Type: GrantFiled: April 6, 2001Date of Patent: September 21, 2004Assignee: WiSys Technology Foundation, Inc.Inventors: Timothy Walston, Scott Cooper, Alireza Rezaie
-
Patent number: 6762286Abstract: The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: March 12, 2001Date of Patent: July 13, 2004Assignee: Regents of the University of MinnesotaInventor: Gary L. Nelsestuen
-
Publication number: 20040132664Abstract: Conjugated kringle protein fragments are disclosed as compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.Type: ApplicationFiled: February 13, 2004Publication date: July 8, 2004Inventors: Jack Henkin, Donald J. Davidson
-
Patent number: 6759384Abstract: The invention provides compounds which specifically inhibit factor Xa activity having the structure A1—A2—(A3)m—B, where m is 0 or 1. A compound of the invention is characterized, in part, in that it exhibits a specific inhibition of factor Xa activity with a Ki≦100 &mgr;M, preferably ≦2 nM, and does not substantially inhibit the activity of other proteases involved in the coagulation cascade. The invention further provides methods of specifically inhibiting the activity of factor Xa and of inhibiting blood clotting in vitro and in an individual and methods of detecting factor Xa levels or activity.Type: GrantFiled: December 14, 1998Date of Patent: July 6, 2004Assignee: Aventis Pharmaceuticals Inc.Inventors: Fahad Al-Obeidi, Michal Lebl, James A. Ostrem, Pavel Safar, Alena Stierandova, Peter Strop, Armin Walser
-
Publication number: 20040110929Abstract: The present invention relates to novel compounds that bind to and inhibit the activity of tissue factor (TF) and mediate a cytolytic immune response.Type: ApplicationFiled: July 11, 2003Publication date: June 10, 2004Inventors: Soren E. Bjorn, Else Marie Nicolaisen, Thomas Dock Steenstrup
-
Patent number: 6747003Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: February 3, 2000Date of Patent: June 8, 2004Assignee: Regents of the University of MinnesotaInventor: Gary L. Nelsestuen
-
Patent number: 6746866Abstract: The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is possible with this cDNA not only to obtain factor XIIIa by gene manipulation in high purity but also to prepare diagnostic aids which permit the analysis of genetic factor XIIIa defects. Furthermore, it is possible on the basis of the amino acid sequence to prepare antibodies which are suitable for diagnostic aids and antibody columns.Type: GrantFiled: June 2, 1995Date of Patent: June 8, 2004Assignee: Aventis Behring GmbHInventors: Ulrich Grundmann, Egon Amann, Gerd Zettlmeissl
-
Publication number: 20040106779Abstract: The present invention relates to a modification of the anion exchange chromatography step in a Factor IX purification process. By the modification the presence of the protease, plasma hyaluronan binding protease, is decreased which minimizes the cleavage of Factor IX and enhances the yield of Factor IX in the purification process.Type: ApplicationFiled: December 3, 2002Publication date: June 3, 2004Inventors: Douglas E. Bigler, Sourav K. Kundu, Holger Lind, Stefan Schulte
-
Patent number: 6737405Abstract: A stabilized protein preparation is described which contains no antithrombin III and is protected against loss of activity during pasteurization by the addition of stabilizers which comprise one or more saccharides as a mixture with more than 0.5 mol/l of one or more amino acids chosen from the group arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts or glutamic acid and its salts. Glycine and/or glutamine can also be additionally added to each of these amino acids. A process for the viral inactivation or viral depletion of a protein preparation of this type which contains the abovementioned stabilizers and is subjected to pasteurization or viral depletion by filtration, centrifugation or treatment with detergents or bactericidal or virucidal agents is also described.Type: GrantFiled: May 7, 2001Date of Patent: May 18, 2004Assignee: Aventis Behring GmbHInventors: Juergen Roemisch, Harald Stauss, Hans-Arnold Stoehr
-
Publication number: 20040063632Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: ApplicationFiled: April 30, 2003Publication date: April 1, 2004Applicant: Schering AktiengesellschaftInventors: David Light, Kirk McLean
-
Publication number: 20040048235Abstract: This invention provides means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions without significant alteration of proteins or other biopolymers by contacting such compositions with selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer.Type: ApplicationFiled: September 9, 2003Publication date: March 11, 2004Applicant: V.I. Technologies, Inc.Inventors: Edward I. Budowsky, Samuel K. Ackerman
-
Patent number: 6693173Abstract: A method is provided for removing citrate, aluminum, and other multivalent ions and contaminants from proteins by adjusting the pH of a solution containing the protein to a pH from about 7 to about 10, and diafiltering the pH-adjusted solution against aqueous solutions which have a low level of ions.Type: GrantFiled: March 13, 2001Date of Patent: February 17, 2004Assignee: Alpha Therapeutic CorporationInventors: Raja R. Mamidi, Leticia R. Regis, Mauro C. Mojica, Hirokazu Ito, Takashi Goto
-
Patent number: 6693075Abstract: The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: April 29, 1999Date of Patent: February 17, 2004Assignee: Regents of the University of MinnesotaInventor: Gary L. Nelsestuen
-
Publication number: 20030224477Abstract: The invention features constructs and related methods for expression of products in mammalian cells, e.g., human cells. Constructs include a human &ggr;-actin, &bgr;-actin, fibronectin, YY1, or &bgr;-tubulin promoter region operably linked to a heterologous nucleic acid sequence.Type: ApplicationFiled: May 31, 2002Publication date: December 4, 2003Inventors: Michael W. Heartlein, Justin Chace Lamsa, Douglas A. Treco, Richard F. Selden, Michael F. Concino, Heidi Kempinski
-
Publication number: 20030220247Abstract: The invention relates to methods of optimizing gamma carboxylation of a vitamin K-dependent protein, methods of generating fully gamma carboxylated vitamin K-dependent protein, and compositions comprising chimeric nucleic acids and proteins for use in treatment of vitamin K-dependent disease states.Type: ApplicationFiled: January 22, 2003Publication date: November 27, 2003Applicants: Children's Hospital of Philadelphia, University of North CarolinaInventors: Katherine A. High, Rodney M. Camire, Peter J. Larson, Darrel W. Stafford
-
Patent number: 6649386Abstract: A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.Type: GrantFiled: October 30, 1998Date of Patent: November 18, 2003Assignee: Quadrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Publication number: 20030211094Abstract: Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation.Type: ApplicationFiled: December 30, 2002Publication date: November 13, 2003Inventor: Gary L. Nelsestuen
-
Patent number: 6645768Abstract: A reagent and kit are disclosed for determining if a patient is hypercoagulable, hypocoagulable or normal. The test involves providing a test sample from the patient and initiating coagulation in the sample in the presence of an activator, which is added to the sample in an amount which will result in intrinsic tenase-dependent fibrin. Then the formation of the intrinsic tenase-dependent fibrin polymerization is monitored over time so as to derive a time-dependent profile, with the results of the fibrin polymerization monitoring determining whether the patient is hypercoagulable, normal or hypocoagulable. The coagulation activator is added in an amount that triggers a thrombin explosion that is dependent on the propagation phase and amplification pathways. In this way, a single assay can assess the hemostatic potential of a sample.Type: GrantFiled: October 27, 2000Date of Patent: November 11, 2003Assignee: bioMerieux, Inc.Inventors: Liliana Tejidor, Trevor Baglin, Hema Doobay, Roger Luddington, Timothy J. Fischer
-
Patent number: 6645724Abstract: The horseshoe crab, Carcinoscorpius rotundicauda Factor C cDNA (CrFC21) has been cloned into a shuttle baculoviral vector and another vector suitable for expression in insect cells. The recombinant baculoviral DNA was then transfected into the insect cells for expression of recombinant Factor C. Recombinant Factor C was found to be immunoreactive and is capable of binding both free and bound/immobilized lipid A. It is enzymatically active when triggered by LPS. The rFC is probably of the two-chain form, being cleaved into the heavy and light chains after activation by Gram negative bacterial endotoxin. As low as 0.01 pg (0.001 ng/ml) of LPS was detectable by the rFC, thus, indicating its potentials as a novel generation of “limulus amoebocyte lysate.Type: GrantFiled: April 7, 1999Date of Patent: November 11, 2003Assignee: National University of SingaporeInventors: Jeak Ling Ding, Bow Ho
-
Publication number: 20030191292Abstract: Filtration methods comprise virus-filtering a solution containing a least one macromolecule. The total salt content of the solution for virus-filtering is within the range of from about 0.2 M up to saturation with the salt. Salts that can be used in the filtering methods include sodium chloride, potassium chloride, sodium acetate, sodium citrate, sodium phosphate, potassium dyhydrophosphate and combinations thereof.Type: ApplicationFiled: November 26, 2002Publication date: October 9, 2003Applicant: Octapharma AG, a Corporation of SwitzerlandInventor: Stefan Winge
-
Patent number: 6627737Abstract: Provided by the present invention are novel methods of factor IX protein recovery and purification.Type: GrantFiled: October 17, 1997Date of Patent: September 30, 2003Assignee: Genetics Institute, LLCInventors: W. Barry Foster, Robert J. Costigan, Duane Bonam, Mary B. Switzer, Rochelle Walsh
-
Publication number: 20030181381Abstract: Factor X analogues having a modification in the region of the natural Factor Xa activation cleavage site, said modification representing a processing site of a protease not naturally cleaving in this region of the Factor X sequence, preparations containing the Factor X analogues according to the invention, and processes for the preparation thereof are described.Type: ApplicationFiled: April 4, 2003Publication date: September 25, 2003Inventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl
-
Patent number: 6610538Abstract: A method of reconstructing laminae of human epithelium corneae in vitro to be used in grafts from cultures of limbar stem cells as well as a method of selecting and transferring such cells to fibrin substrate.Type: GrantFiled: September 25, 2001Date of Patent: August 26, 2003Assignee: Provincia Italiana Della Congregazione Dei Figli Dell' Immacolata Concezione - Istituto Dermopatico Dell' ImmacolataInventors: Michele De Luca, Graziella Pellegrini
-
Publication number: 20030148953Abstract: The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid sequences corresponding to known human FVIII sequences, wherein the APC cleavage sites, Arg336 and Ile562, are mutated. The nucleic acid sequences of the present invention further encode amino acid sequences corresponding to known human FVIII sequences, wherein the B-domain is deleted, the von Willebrand factor binding site is deleted, a thrombin cleavage site is mutated, an amino acid sequence spacer is inserted between the A2- and A3-domains.Type: ApplicationFiled: October 29, 2002Publication date: August 7, 2003Applicant: UNIVERSITY OF MICHIGANInventors: Randal J. Kaufman, Steven W. Pipe
-
Publication number: 20030138914Abstract: Factor X&Dgr; analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179, preparations containing these factor X&Dgr; analogues, and processes for the preparation thereof are described.Type: ApplicationFiled: January 21, 2003Publication date: July 24, 2003Inventors: Michele Himmelspach, Michael Pfleiderer, Falko-Guenter Falkner, Johann Eibl, Friedrich Dorner, Uwe Schlokat
-
Publication number: 20030130191Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.Type: ApplicationFiled: October 28, 2002Publication date: July 10, 2003Inventors: Egon Persson, Ole Hvilsted Olsen
-
Publication number: 20030124705Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.Type: ApplicationFiled: March 20, 2002Publication date: July 3, 2003Inventors: Leslie Roy Berry, Maureen Andrew, Anthony Kam Chuen Chan
-
Patent number: RE38431Abstract: The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to stable liquid formulations of Factor VIII and Factor IX that can be administered by injection or infusion to provide a constant level of the coagulation factor in the blood.Type: GrantFiled: August 26, 2002Date of Patent: February 17, 2004Assignees: The American National Red Cross, The Coalition for Hemophilia BInventors: Shirley I. Miekka, William N. Drohan, Thomas R. Jameson, John R. Taylor, Jr., Manish P. Singh, Martin J. MacPhee